Ascendis Pharma A/S (NASDAQ:ASND) Issues Quarterly Earnings Results, Beats Expectations By $1.05 EPS

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Thursday. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $1.05, FiscalAI reports. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $418.71 million during the quarter, compared to the consensus estimate of $409.40 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• Q3 product revenue rose 89% year over year to €366 million, including €291 million from YORVIPATH, €59 million from SKYTROFA and €16 million from newly launched YUVIWEL.
• YORVIPATH continued to grow, with U.S. demand described as steady and revenue increasing €39 million sequentially; the company said it expects further growth as it expands commercial availability, including 15 additional markets anticipated in 2027.
• YUVIWEL had about 340 U.S. patients enrolled through October, with more than 80% approved for reimbursement. Ascendis expects a European Commission decision before year-end and, if approved, plans a Germany launch in early 2027.
• Operating cash flow was €189 million in Q3, and Ascendis raised its 2026 expectation to at least €600 million; it ended the quarter with €964 million in cash. Management reiterated its longer-term revenue goals of more than €5 billion in 2030 and €10 billion in 2035, which depend on continued product growth, geographic expansion and pipeline development.
• The company is advancing label-expansion and combination-therapy programs, including a Phase III achondroplasia combination trial that has begun recruiting. Ascendis said the trial was redesigned after regulatory feedback to include a growth-hormone monotherapy arm, which enlarged the study and delayed it by a few months.

Ascendis Pharma A/S Stock Up 2.6%

NASDAQ:ASND traded up $6.80 on Thursday, reaching $266.08. The stock had a trading volume of 718,268 shares, compared to its average volume of 700,453. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $242.59 and a 200 day moving average of $239.48. The stock has a market cap of $16.60 billion, a P/E ratio of 20.67 and a beta of 0.40. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Citigroup decreased their target price on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, October 26th. Barclays lowered their target price on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, UBS Group began coverage on Ascendis Pharma A/S in a research report on Thursday, October 15th. They set a “buy” rating and a $269.00 price target on the stock. Nineteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $305.95.

Insider Activity

In related news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their position. The SEC filing for this purchase provides additional information. 40.00% of the stock is owned by company insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.